Of note, CLASSIC (Noh; Lancet Onc 2014) nor ARTIST (Lee; JCO 2012) evaluated other histologic subtypes, is the approach to treatment any different tha...
New answer by Medical Oncologist at Henry Ford Cancer Institute (HFCI) (January 15, 2020)
Prospective data will not be available. In the absence of better clinical or molecular guidance, I will treat such patients same way I treat adenocarcinomas.